Head & Neck Cancers | Specialty

Prognostic Factors for HNSCC

November 7th 2016

Underlying Biology of HPV-Positive and -Negative HNSCC

November 7th 2016

Speed Critical With Anaplastic Thyroid Cancer Diagnosis, Treatment

November 3rd 2016

Enrolling clinical trials can be a long process, especially in rare diseases with limited patient populations. This is a particularly significant issue for patients with anaplastic thyroid cancer, an extremely rare and aggressive disease.

Jena D. French on Anti-PD-1/Lenvatinib Combo in Differentiated Thyroid Cancer

November 3rd 2016

Jena D. French, PhD, instructor of medicine, division of endocrinology, metabolism and diabetes, Anschutz Medical Campus, University of Colorado, discusses the potential for immunotherapy combinations with lenvatinib in differentiated thyroid cancer.

Immunotherapy Potentially Promising for Treatment of ATC

October 21st 2016

Given the poor prognoses often seen in patients with anaplastic thyroid cancer, researchers are seeking novel therapies that may hold more promise than surgery or radiation.

Expert Emphasizes Lack of Treatment Options for Medullary Thyroid Cancer

October 20th 2016

Though some patients with medullary thyroid cancer can live with their disease without progression for long periods of time, the majority will eventually enter a phase in which their cancer becomes much more aggressive.

Bridgett Harr on Managing Long-term Side Effects in Head and Neck Cancer

October 19th 2016

Bridgett Harr, CNP, radiation oncology, Cleveland Clinic, discusses survivorship and managing long-term side effects in head and neck cancer.

Dr. Cohen on Biomarker Testing in Head and Neck Cancer

October 15th 2016

Ezra Cohen, MD, associate director, Moores Cancer Center, professor of Medicine, University of California, San Diego Health System, discusses biomarker testing in patients with head and neck cancer.

No PFS Benefit in Recurrent Head and Neck Cancer With Addition of Immunotherapy

October 12th 2016

Adding a Toll-like receptor 8 agonist to standard care for patients with recurrent or metastatic squamous cell carcinoma of the head and neck failed to improve progression-free survival.

Dr. Burtness on Immunotherapy and Chemotherapy in Head and Neck Cancer

October 12th 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the potential benefits of using immunotherapy and chemotherapy together in head and neck cancer.

Dr. Randolph on Future Treatment Approaches in Thyroid Cancer

October 11th 2016

Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts General Hospital, discusses the future methods of treating patients with thyroid cancer.

Dr. Jonas de Souza on the Impact of Pembrolizumab Approval in Head and Neck Cancer

October 5th 2016

​Jonas de Souza, MD, assistant professor of medicine, University of Chicago, discusses the approval of pembrolizumab for relapsed head and neck cancer patients who are platinum-refractory

KRAS-Variant HNSCC Outcomes May Improve With Cetuximab

October 4th 2016

Patients with head and neck cancer whose disease is associated with KRAS variant had significantly better progression-free survival and overall survival when treated with the monoclonal antibody cetuximab, according to findings of a retrospective analysis of a randomized trial.

New Classification System Reflects Improved Prognosis for HPV+ Oropharyngeal Cancer

September 22nd 2016

Researchers have created a new classification system for oropharyngeal cancer that is adjusted for the improved prognosis of patients with HPV-positive disease.

Published Results Affirm Efficacy of Fixed-Dose Pembrolizumab in HNSCC

September 22nd 2016

The FDA-approved fixed dose of 200 mg of pembrolizumab administered once every 3 weeks yielded durable responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Pembrolizumab Approval Is Tip of the Iceberg for Immunotherapy in HNSCC

September 21st 2016

Barbara A. Burtness, MD, discussed the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.

Dr. Burtness on Ongoing Trials of Immunotherapy in Head and Neck Cancer

September 21st 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses some of the ongoing trials currently examining the use of immunotherapy to treat patients with head and neck cancer.

Dr. Frakes on Late Toxicities in HPV-Associated Oropharynx Squamous Cell Carcinoma

September 16th 2016

Jessica Frakes, MD, assistant member, Department of Radiation Oncology, Moffitt Cancer Center, discusses some of the late toxicities seen in patients with HPV-positive oropharynx squamous cell carcinoma.

Dr. Schoenfeld on Synergy Between Radiation and Immunotherapy in SCCHN

September 13th 2016

Dr. Anderson on Superoxide Dismutase Mimetic GC4419 in Treating Patients With Oropharyngeal Carcinoma

September 10th 2016

Carryn Anderson, MD, assistant professor of Radiation Oncology, University of Iowa, discusses a phase Ib/IIa study of superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavitiy or oropharyngeal carcinoma.